Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

This research study is testing a new medication called Eloralintide (also known as LY3841136). It's designed for adults who are overweight or have obesity but do not have type 2 diabetes. The main goal is to find out if Eloralintide can effectively help people manage their weight and if it's safe to use. Some people will receive Eloralintide, while others will receive a placebo (a dummy treatment). The study has two parts: a main phase lasting about 75 weeks, and an extended phase for those with prediabetes, which will continue for another two years. This helps researchers understand the longer-term effects of the medication.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Eli Lilly und Unternehmen
Einschreibeziel
1,980
Starten
06 Feb 2026
Geschätzte Fertigstellung
01 Jul 2030

Worum geht es in dieser Studie?

This study is designed to investigate a new medication called Eloralintide. It's for adults who are overweight or have obesity and are looking for help with weight management, but importantly, they mustn't have type 2 diabetes. The scientists running this study want to learn two main things: first, how well Eloralintide works to help people lose weight, and second, if it's safe to use.

To do this, some people in the study will be given Eloralintide, while others will receive a placebo. A placebo looks just like the study drug but doesn't contain any active medicine. This comparison is important because it helps researchers understand if any changes are truly due to the Eloralintide or if they might have happened anyway. The study is divided into a main phase and an extension phase to get a full picture of the medication's effects.

Finding new ways to manage weight is important for many people, as being overweight or having obesity can sometimes lead to other health problems. This research could help us understand if Eloralintide could be a new option for individuals in the future.

Wichtige Erkenntnisse

  • Tests a new weight-loss medication called Eloralintide.
  • For adults who are overweight or have obesity, but without type 2 diabetes.
  • Compares Eloralintide against a placebo (dummy treatment).
  • Study lasts about 75 weeks, with an optional extension for some.
  • Aims to check both how well it works and if it's safe.
  • Regular health checks throughout your participation.

Wer könnte berechtigt sein?

To join this study, you need to be an adult (18 or older) and fit certain health measurements. For instance, your Body Mass Index (BMI) needs to be 30 or higher. If your BMI is 27 or higher, you could also qualify if you have one of these weight-related health conditions: high blood pressure, unhealthy cholesterol levels, sleep apnea (where you stop breathing briefly during sleep), or heart disease. You also need to have tried to lose weight with diet changes before and your weight must have been stable for the three months leading up to the study.

However, some things would mean you can't take part. This includes having had or planning to have weight-loss surgery (like liposuction is okay if it was over a year ago). Similarly, if you've had certain procedures inside your gut for weight loss, you might not be eligible. You also can't have type 1 or type 2 diabetes. If you've had a recent heart attack, stroke, or other serious heart problems in the last three months, or severe heart failure, you won't be able to join. Finally, if you've used other weight-loss medications or remedies in the last three months, you won't qualify.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Is your Body Mass Index (BMI) 30 or higher, or 27 or higher with conditions like high blood pressure or sleep apnea?
  3. Have you tried to lose weight through dieting before?
  4. Have you had stable weight for the past 3 months?
  5. Do you NOT have type 1 or type 2 diabetes?
  6. Have you NOT had any major heart problems (like a heart attack or stroke) in the past 3 months?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you'll be involved for about 75 weeks, which is roughly a year and a half. During this time, you'll have regular visits to the study clinic where doctors and nurses will check your health, measure your weight, and ask about your well-being. You'll be given either the study medication (Eloralintide) or a placebo, which you'll need to take as instructed.

For some participants who have 'prediabetes' (meaning their blood sugar levels are higher than normal but not yet at the level of type 2 diabetes), the study will continue for an extra two years after the main phase finishes. This 'extension phase' will help researchers understand the long-term effects of the medication in this specific group. Throughout the study, you'll be actively monitored, and you'll have scheduled appointments to ensure your safety and to track your progress.

Potenzielle Risiken und Vorteile

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study could be receiving a new medication that might help you manage your weight. You’ll also receive regular medical check-ups and monitoring by a healthcare team. However, there are potential risks, such as experiencing side effects from the study medication, though these are carefully monitored. It's also possible that the medication might not work for you, or that you could receive the placebo. Your health and safety are paramount, and you are free to withdraw from the study at any time, for any reason, without affecting your usual medical care.

Standorte (158)

  • MFA Clinical Research
    Verifizierte Postleitzahl
    Tuscaloosa, United States· Rekrutierung
  • Headlands Research - Scottsdale
    Verifizierte Postleitzahl
    Scottsdale, Vereinigte Staaten· Rekrutierung
  • Neighborhood Healthcare Institute of Health
    Verifizierte Postleitzahl
    Escondido, United States· Rekrutierung
  • Ark Clinical Research - Fountain Valley
    Verifizierte Postleitzahl
    Fountain Valley, Vereinigte Staaten· Rekrutierung
  • Desert Oasis Healthcare Medical Group
    Verifizierte Postleitzahl
    Palm Springs, Vereinigte Staaten· Rekrutierung
  • Peninsula Research Associates
    Verifizierte Postleitzahl
    Rolling Hills Estates, United States· Rekrutierung
  • Care Access - Sacramento
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten· Rekrutierung
  • Southern California Clinical Research
    Verifizierte Postleitzahl
    Santa Ana, United States· Rekrutierung
  • University Clinical Investigators, Inc.
    Verifizierte Postleitzahl
    Tustin, Vereinigte Staaten· Rekrutierung
  • Chase Medical Research, LLC
    Verifizierte Postleitzahl
    Waterbury, United States· Rekrutierung
  • JEM Research Institute
    Verifizierte Postleitzahl
    Atlantis, Vereinigte Staaten· Rekrutierung
  • BioMed Research & Medical Center
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is Eloralintide?

Eloralintide is a new medication being tested in this study to see if it can help adults who are overweight or have obesity manage their weight.

Was ist ein 'Placebo'?

A placebo is a 'dummy' treatment that looks just like the real medication but contains no active ingredients. It's used so researchers can compare its effects to the actual drug.

Wie lange wird die Studie dauern, wenn ich teilnehme?

The main part of the study will last about 75 weeks (around 1.5 years). If you have prediabetes, you might continue for another 2 years in an extension phase.

Can I join if I have diabetes?

No, this study is specifically for people who do not have type 1 or type 2 diabetes.

Will I know if I'm getting the real medication or the placebo?

No, during the study, neither you nor your study doctor will know whether you are receiving Eloralintide or the placebo. This is to ensure fair and unbiased results.

Wie Sie mehr erfahren können

Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study of Eloralintide (LY3841136) in Participants With Obe… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.